Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Eptinezumab in Healthy Chinese Subjects
NCT05045781Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eptinezumab in migraine (2 arms), sponsored by Lundbeck. Primary endpoints: Area under the concentration-time curve from time zero to infinity, Maximal observed plasma concentration and 3 more. Started Apr 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05045781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045781.